论文部分内容阅读
目的对比卡维地洛与美托洛尔治疗慢性心力衰竭(CHF)的临床疗效。方法将85例CHF患者随机分为研究组和对照组。在常规治疗的基础上,研究组(43例)加用卡维地洛,对照组(42例)加用美托洛尔。对比观察两组患者的左室舒张末期内径(LVEDd)、左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI),近远期疗效及不良反应。结果治疗后研究组的LVEDd降低幅度,LVEF、SV、CI升高幅度均优于对照组,组间比较2个月时无统计学差异(P>0.05),6个月、12个月时差异均有显著统计学意义(P<0.01);2组总有效率比较,治疗后2个月时无统计学差异(P>0.05),6个月、12个月时差异均有显著统计学意义(P<0.05)。不良反应组间比较差异无统计学意义(P>0.05)。结论卡维地洛在改善心功能方面具有更好的远期效果,且安全性较佳,在CHF的临床治疗中可优先选择。
Objective To compare the clinical efficacy of carvedilol and metoprolol in the treatment of chronic heart failure (CHF). Methods 85 CHF patients were randomly divided into study group and control group. On the basis of routine treatment, the study group (43 cases) plus carvedilol, the control group (42 cases) plus metoprolol. The left ventricular end-diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac index (CI), short-term and long-term effects and adverse reactions were observed. Results After treatment, the decrease of LVEDd, the increase of LVEF, SV and CI in the study group were better than those in the control group. There was no significant difference between the two groups (P> 0.05), the difference of 6 months and 12 months (P <0.01). There was no significant difference in the total effective rate between the two groups (P> 0.05), but there was a significant difference at 6 and 12 months (P <0.05). There was no significant difference between the adverse reaction groups (P> 0.05). Conclusion Carvedilol has better long-term effect in improving cardiac function and better safety, and may be given priority in the clinical treatment of CHF.